

Supplementary Information

Small Molecules Targeting Coxsackievirus A16 Capsid Inactivate Viral Particles and Prevent Virus Binding

Chien-Ju Lin¹, Ching-Hsuan Liu^{2,3}, Jonathan Y. Wang⁴, Chun-Ching Lin^{1,5}, Yi-Fang Li⁵,
Christopher D. Richardson^{3,6}, and Liang-Tzung Lin^{2,7,#}

¹ School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

² Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

³ Department of Microbiology & Immunology, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada

⁴ Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas 78712, United States of America

⁵ Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 80708, Taiwan

⁶ Department of Pediatrics and Canadian Center for Vaccinology, Izaak Walton Killam Health Centre, Halifax, Nova Scotia B3K 6R8, Canada

⁷ Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan

#CORRESPONDING AUTHOR

Liang-Tzung Lin, Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, No. 250, Wu-Hsing Street, Taipei 11031, Taiwan, Tel: +886-2-2736-1661 ext. 3911, Fax: +886-2-2736-1661 ext. 3921, E-mail: ltlin@tmu.edu.tw.

Supplementary Figure




Fig. S1. Ultracentrifugation analysis of CVA16 particles treated with the tannins.

Polyethylene glycol-8000 (PEG8000)-concentrated CVA16 virions were treated with DMSO (0.25%), CHLA (20 μ M) or PUG (25 μ M) for 1 h at 37 $^{\circ}$ C. The drug-treated virus samples were layered onto a 20% to 60% sucrose gradient in 50 mM Tris-HCl (pH = 7), and then subjected to ultracentrifugation in a Beckman SW40 Ti rotor (Beckman Coulter; Brea, CA, USA) at 35,000 rpm for 3 h at 4 $^{\circ}$ C. Sedimentation of the virions at the end of the ultracentrifugation run is shown (a). Nine fractions (1 ml/fraction) from the ultracentrifugation were subsequently taken from top to bottom and subjected to Western blot analysis (b) and optical density assessment (c). For Western blot analysis, 18 μ l of the fractions were subjected to SDS-PAGE and then transferred to PVDF membrane, which was blocked with 5% BSA for 1 h; the membrane was subsequently probed using anti-VP1 primary antibody (1:2000; Millipore) and anti-mouse HRP-conjugated secondary antibody (1:2000; Invitrogen) before detecting and imaging immunoreactive proteins using enhanced chemiluminescence reagent (Western Lightning ECL Pro; PerkinElmer, Waltham, MA, USA) and a Bio-Rad ChemiDoc Imager (Bio-Rad; Hercules, CA, USA). For measurement of optical density, individual fractions from the ultracentrifugation were diluted 5 times using ddH₂O and then analyzed using a spectrophotometer (Eppendorf; Hamburg, Germany) at 260 nm.